Cargando…

Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis

Previous evidence suggests that the humanized anti-VEGF antibody bevacizumab increases thrombosis risk in glioma patients. Here, we comprehensively assessed the risk of adverse vascular events in adult glioma patients receiving bevacizumab therapy. Systematic searches of MEDLINE, EMBASE, and the Coc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiaoqing, Huang, Rongzhong, Xu, Zhongye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589758/ https://www.ncbi.nlm.nih.gov/pubmed/26423913 http://dx.doi.org/10.1038/srep14698

Ejemplares similares

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review
por: Alimohammadi, Ehsan, et al.
Publicado: (2020)

Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis
por: Liao, Guixiang, et al.
Publicado: (2019)

The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme
por: Lai, Rose, et al.
Publicado: (2010)

Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab
por: Wagle, Naveed, et al.
Publicado: (2010)

Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma
por: Matsuda, Masahide, et al.
Publicado: (2022)

The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis
por: Liao, Ke-Li, et al.
Publicado: (2018)

Infrared Thermography in Surgery of Newly Diagnosed Glioblastoma Multiforme: A Technical Case Report
por: Naydenov, Emanuil, et al.
Publicado: (2017)

The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients
por: Poulsen, Hans Skovgaard, et al.
Publicado: (2014)

Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme
por: Aherne, Noel J., et al.
Publicado: (2014)

Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study
por: Annavarapu, Srinivas, et al.
Publicado: (2021)

New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab
por: Moustakas, Argirios, et al.
Publicado: (2010)

Prognostic significance of concomitant radiotherapy in newly diagnosed glioblastoma multiforme: a multivariate analysis of 116 patients
por: Okumus, Nilgun Ozbek, et al.
Publicado: (2012)

Management of dermatologic adverse events associated with tumor treating fields in patients with glioblastoma multiforme: A 27-case series
por: Chen, Xiaoxue, et al.
Publicado: (2022)

Prediction of Glioblastoma Multiform Response to Bevacizumab Treatment Using Multi-Parametric MRI
por: Najafi, Mohammad, et al.
Publicado: (2012)

Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
por: Shields, Lisa BE, et al.
Publicado: (2013)

Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme
por: Liu, Zhiguang, et al.
Publicado: (2015)

Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis
por: Kaka, Nagham, et al.
Publicado: (2019)

In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma
por: Hawkins-Daarud, Andrea, et al.
Publicado: (2015)

Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab
por: Wen, Qiuting, et al.
Publicado: (2014)

Factors Influencing the Improvement of Activities of Daily Living during Inpatient Rehabilitation in Newly Diagnosed Patients with Glioblastoma Multiforme
por: Natsume, Keisuke, et al.
Publicado: (2022)

Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan
por: Almubarak, Mohammed, et al.
Publicado: (2008)

Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study
por: Nagane, Motoo, et al.
Publicado: (2022)

Glioblastoma Multiforme in the over 70's: “To treat or not to treat with radiotherapy?”
por: Glynn, Aisling M., et al.
Publicado: (2019)

An Update in the Use of Antibodies to Treat Glioblastoma Multiforme
por: Hernández-Pedro, Norma Y., et al.
Publicado: (2013)

The role of metabolic therapy in treating glioblastoma multiforme
por: Maroon, Joseph C., et al.
Publicado: (2015)

Glioblastoma Multiforme
por: Sheehan, Jonas M., et al.
Publicado: (2012)

Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials
por: Du, Chigang, et al.
Publicado: (2016)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Achievement of Three Year Remission with Bevacizumab and Irinotecan in Recurrent Glioblastoma Multiforme: A Case Report
por: Vivekanandarajah, Abhirami, et al.
Publicado: (2011)

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts
por: Nishri, Yossi, et al.
Publicado: (2022)

Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis
por: Ballo, Matthew T., et al.
Publicado: (2023)

A Multi-Site Phase I Trial of Veliparib with Standard Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
por: Kleinberg, Lawrence, et al.
Publicado: (2023)

Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
por: Ngo, Doan T. M., et al.
Publicado: (2020)

The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial
por: Weller, Johannes, et al.
Publicado: (2023)

Advances in the treatment of newly diagnosed glioblastoma
por: Theeler, Brett J., et al.
Publicado: (2015)

A Review of Newly Diagnosed Glioblastoma
por: Oronsky, Bryan, et al.
Publicado: (2021)

Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
por: Rosenfeld, Myrna R, et al.
Publicado: (2014)

Glioblastoma multiforme – an overview
por: Urbańska, Kaja, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gh5f57thp5na3h6spo2d5b0oo4